Product Development

Delivery Devices

Our mission at Retina Specialty Institute is to bring the newest and best available research and therapies to our patients on the Gulf Coast. Towards this end, we are developing more effective, safer technologies to treat common blinding diseases such as Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR). Currently wet or neovascular AMD is treated by frequent injections into the eye, intravitreal injections, and DR is treated by injections and laser, which have inherent risks and can be potentially destructive. Therefore, more effective and less invasive treatments are needed.

Drug delivery to the retina can be accomplished by:

  • Direct Injection
  • Eye Drops
  • Systemic Medicine
  • placement of Medicine Around the Eye

 

Typically eye drops will not achieve high enough concentrations in the retina to be effective against AMD or DR, and systemic medicines are associated with systemic side effects. Placement of medicine around the eye for some compounds represents an ideal delivery system where a safe and high retinal concentration of a compound can be achieved in a relatively non-invasive manner.

At Retina Specialty Institute, we have developed both a stable small compound as well as a sustained delivery device. RFE-007-CAI is effective against abnormal vessels observed in DR and AMD and is predicted to treat these common diseases effectively after an annual administration. This delivery device relies on a stable small molecule that can be placed on the outside of the eye so that the compound can diffuse through the sclera or white part of the eye to the retina.

The delivery device system is designed for use with either a solid pellet or liquid medicine that can be easily replaced every 6-12 months. It is therefore our hope that these technologies developed at Retina Specialty Institute will provide the next generation of treatments for AMD and DR.